("we", "us", "the Company" or "Darwin Bio") has successfully implemented a key step in the divestiture and transfer of its consumer healthcare business, which was successfully incubated on its internal technology platform. The key step of divestment and transfer of the consumer business, which was successfully incubated on our internal technology platform, has been successfully implemented.
Darwin Bio, as a high-tech enterprise based on innovative biotechnology research and development, has been committed to making breakthroughs in biopharmaceuticals, biomaterials and other technological fields. The company's research focus involves stroke,tachycardia, neurodegenerative diseases such as Alzheimer's disease, and degenerative joint lesions, and some research results have been achieved.
In order to better focus on its core business areas, the Company decided to divest and transfer the business of the consumer healthcare segment, which was successfully incubated by its internal technology platform. After a step-by-step implementation, the key steps for the divestment and transfer of this business have been successfully implemented.Missi(Beijing) Culture Communication Co., Ltd. (hereinafter referred to as "MiXi"), as the transferee, has signed the transaction documents with the relevant parties, and the relevant legal procedures are being carried out in an orderly manner, and it is expected that the formal delivery will be completed soon.
The company's consumer medical section business mainly involves repair products for hair follicles, skin and oral cavity, which have a wide range of application prospects in the fields of beauty and health. Misi highly recognizes the value and potential of Darwin Bio's consumer medical section business. After the completion of this transaction, Misi will deeply empower the continuous operation and development of the consumer medical section business by virtue of its rich experience and resources in the field of culture and communication as well as its uniqueness in shaping the brand image and spreading the brand value.
Darwin Bio will focus on the research and development of innovative biotechnology to promote the progress of medical science and technology. We will continue to invest resources and energy to strengthen our R&D team, improve our technology and make greater contributions to human health. The Company is full of confidence in the future and believes that this transaction will bring the Company a broader space for development and better prospects for development. We will continue to maintain close contact with partners from all walks of life to jointly promote the progress of medical science and technology for the benefit of human health. Thank you for your continuous attention and support to the Company. We will continue to work hard to provide you with better products and services.
English 
Chinese